COYA

+ Watchlist + Portfolio

Coya Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.97
52-Week Range: $3.71 – $7.75
Market Cap: $114.01M
P/E (TTM): —
EPS (TTM): -1.04
Dividend Yield: —

Advanced Metrics

Price/Book: 2.63
PEG Ratio: —
Return on Equity: -60.54%
Return on Assets: -32.27%
Gross Margin: -108.68%
Operating Margin: -2890.45%
Profit Margin: -270.22%
Current Ratio: 13.40
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-11.97M
Revenue Growth: 49.00%
Earnings Growth: —
Enterprise Value: $70.35M

COYA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$6.00M	$3.55M	$7.95M
Research & Development	$4.94M	$6.04M	$11.89M	$19.02M
Selling, General & Admin	$4.85M	$7.83M	$8.89M	$11.45M
Operating Expenses	$9.81M	$13.91M	$20.80M	$30.50M
Operating Income	-$9.81M	-$7.90M	-$17.25M	-$22.56M
EBITDA	-$9.78M	-$7.88M	-$17.22M	-$22.53M
Pretax Income	-$12.24M	-$7.26M	-$15.60M	-$21.22M
Income Tax	$0.00	$723.85K	-$720.29K	$3.09K
Net Income	-$12.24M	-$7.99M	-$14.88M	-$21.23M
Diluted EPS	-4.73	-0.79	-0.98	-1.27
Diluted Shares	2.59M	10.16M	15.24M	16.73M

COYA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.93M	$32.63M	$38.34M	$46.82M
Receivables	$0.00	$7.50M	$730.58K	$0.00
Current Assets	$7.18M	$41.20M	$44.31M	$49.94M
Total Assets	$8.40M	$41.26M	$44.35M	$49.95M
Current Liabilities	$3.82M	$5.05M	$3.82M	$5.87M
Long-Term Debt	$12.97M	—	—	—
Total Debt	$12.97M	—	—	—
Total Liabilities	$16.79M	$5.63M	$4.77M	$6.92M
Retained Earnings	-$17.87M	-$25.86M	-$40.74M	-$61.96M
Shareholders' Equity	-$8.39M	$35.64M	$39.58M	$43.03M
Working Capital	$3.36M	$36.14M	$40.48M	$44.07M
Net Debt	$7.03M	—	—	—

COYA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.24M	-$11.19M	-$10.29M	-$10.74M
Free Cash Flow	-$7.24M	-$11.19M	-$10.29M	-$10.74M
Depreciation & Amortisation	$27.36K	$27.36K	$27.36K	$27.36K
Stock-Based Compensation	$207.35K	$872.25K	$2.66M	$4.29M
Investing Cash Flow	-$525.00K	-$543.19K	-$25.00K	-$1.16M
Financing Cash Flow	$9.36M	$38.43M	$16.03M	$20.39M
Net Change in Cash	$1.59M	$26.69M	$5.71M	$8.48M

COYA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$257.88K	$163.62K	$3.56M	$3.96M	$251.15K
Research & Development	$5.21M	$3.66M	$3.43M	$6.71M	$4.11M
Selling, General & Admin	$2.71M	$2.91M	$2.56M	$3.27M	$3.78M
Operating Expenses	$7.93M	$6.58M	$6.00M	$9.99M	$7.89M
Operating Income	-$7.68M	-$6.41M	-$2.43M	-$6.03M	-$7.64M
EBITDA	-$7.67M	-$6.41M	-$2.43M	-$6.02M	-$7.64M
Pretax Income	-$7.31M	-$6.09M	-$2.12M	-$5.71M	-$7.21M
Income Tax	$0.00	$0.00	—	—	$0.00
Net Income	-$7.31M	-$6.09M	-$2.12M	-$5.71M	-$7.21M
Diluted EPS	-0.44	-0.36	-0.13	—	-0.32
Diluted Shares	16.72M	16.72M	16.73M	—	22.64M

COYA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$35.53M	$29.76M	$28.13M	$46.82M	$50.72M
Receivables	$0.00	$0.00	$0.00	$0.00	—
Current Assets	$38.37M	$33.43M	$32.02M	$49.94M	$53.26M
Total Assets	$38.40M	$33.45M	$32.04M	$49.95M	$53.27M
Current Liabilities	$4.34M	$4.50M	$3.67M	$5.87M	$3.55M
Total Liabilities	$5.04M	$5.14M	$4.76M	$6.92M	$4.30M
Retained Earnings	-$48.04M	-$54.14M	-$56.25M	-$61.96M	-$69.17M
Shareholders' Equity	$33.37M	$28.31M	$27.28M	$43.03M	$48.97M
Working Capital	$34.03M	$28.93M	$28.36M	$44.07M	$49.72M

COYA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.83M	-$5.77M	-$1.13M	-$1.01M	-$6.21M
Free Cash Flow	-$2.83M	-$5.77M	-$1.65M	-$491.13K	-$6.21M
Depreciation & Amortisation	$6.84K	$6.84K	$6.84K	$6.84K	$2.81K
Stock-Based Compensation	$1.08M	$1.04M	$1.07M	$1.10M	$2.20M
Investing Cash Flow	$0.00	$0.00	-$516.00K	-$648.61K	-$885.00K
Financing Cash Flow	$19.14K	$0.00	$19.14K	$20.35M	$11.00M
Net Change in Cash	-$2.81M	-$5.77M	-$1.63M	$18.69M	$3.90M

Market Snapshot

About

Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary medicines to modulate the function of regulatory T cells (Tregs) for treatment of autoimmune, neurodegenerative, and inflammatory diseases. Headquartered in Houston, Texas, the company's lead programs target conditions including amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and Alzheimer's disease. Coya's therapeutic approach focuses on enhancing Treg function to restore immune homeostasis and reduce inflammation. The company's pipeline includes combination biologic therapies designed to expand and activate Tregs in diseased tissues.